Cargando…

5572697 TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales:	Andemariam, B., Inati, A., Colombatti, R., Minniti, C., Brown, C., Hottmann, M., Gray, S., Hoppe, C., Davis, M., Yue, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112492/ http://dx.doi.org/10.1097/01.HS9.0000928300.84715.89

Ejemplares similares

P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, B., et al.
Publicado: (2022)

A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease
por: Mayer, Christina Lourdes, et al.
Publicado: (2023)

S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE
por: Tarasev, M, et al.
Publicado: (2022)

S119: PRELIMINARY RESULTS OF A PHASE 1 STUDY IN HEALTHY SUBJECTS ADMINISTERED INCLACUMAB, A FULLY HUMAN IGG4 ANTI-P-SELECTIN MONOCLONAL ANTIBODY IN DEVELOPMENT FOR TREATMENT OF SICKLE CELL DISEASE
por: Mayer, C, et al.
Publicado: (2022)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin
por: Schmitt, Christophe, et al.
Publicado: (2015)

P-059: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 RESOLVE TRIAL INVESTIGATING THE EFFICACY OF VOXELOTOR WITH STANDARD OF CARE IN THE RESOLUTION OF LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE
por: C., MINNITI, et al.
Publicado: (2022)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Andemariam, B., et al.
Publicado: (2022)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

5579775 OVERVIEW OF THE VOXELOTOR POST-APPROVAL CLINICAL RESEARCH PROGRAM
por: Minniti, C., et al.
Publicado: (2023)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

P129: NARRATING SICKLE CELL DISEASE: THE EXPERIENCES OF PATIENTS AND CARGIVERS
por: De Franceschi, L, et al.
Publicado: (2022)

P1429: IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM
por: Federici, Chiara, et al.
Publicado: (2023)

Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial
por: Stähli, Barbara E., et al.
Publicado: (2016)

COX-2 and E-selectin expression evaluation after acute normovolemic hemodilution
por: Kahvegian, M, et al.
Publicado: (2009)

5610823 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P., et al.
Publicado: (2023)

5613512 ASSESSMENT OF CHRONIC PAIN IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE IN ITALY: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY C.PIATTELLINI1, V.MUNARETTO2, G.REGGIANI2, I.BAIDO2, E.MARAN2, A.BIFFI2, F.BENINI1, A.ZANIN1 AND R.COLOMBATTI2
por: Piattellini, C.P., et al.
Publicado: (2023)

P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Bartolucci, P, et al.
Publicado: (2022)

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
por: Nelson, M, et al.
Publicado: (2010)

5610325 VARIABILITY OF OXYGENSCAN PARAMETERS ACCORDING TO THE TYPE OF THERAPY IN CHILDREN WITH SICKLE CELL DISEASE: PRELIMINARY DATA FROM A FEASIBILITY STUDY
por: Reggiani, G., et al.
Publicado: (2023)

P134: THE AREAL PROJECT: A VIRTUAL REALITY APPLICATION TO SUPPORT THE THERAPEUTIC EXPERIENCE AND THERAPY EDUCATION OF ADULT PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE
por: Megale, V, et al.
Publicado: (2022)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
por: Colombatti, R., et al.
Publicado: (2023)

P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
por: A., IDRIZOVIC, et al.
Publicado: (2022)

P127: HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON- A REAL-WORLD EXPERIENCE
por: Adlette Inati, A, et al.
Publicado: (2022)

P118: THE ROLE OF HEMOGLOBIN AND HEMOLYSIS ON TRANSCRANIAL DOPPLER VELOCITIES IN CHILDREN WITH SICKLE CELL DISEASE: DATA FROM A NATURAL HISTORY COHORT
por: Reggiani, G, et al.
Publicado: (2022)

P-selectin, an important mediator of angiogenesis in females: the role of estradiol
por: Koch, AE, et al.
Publicado: (2004)

5612539 TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M., et al.
Publicado: (2023)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2022)

P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)
por: Callaghan, M, et al.
Publicado: (2022)

Usefulness of soluble E-selectin in the clinicopathologic assessment of acute lung injury/acute respiratory distress syndrome
por: Kakihana, Y, et al.
Publicado: (2009)

P-001: COMMON DATA MODEL FOR SICKLE CELL DISEASE SURVEILLANCE: CONSIDERATIONS AND IMPLICATIONS
por: M., SMELTZER, et al.
Publicado: (2022)

P-036: PIEZO1 ACTIVATION AUGMENTS SICKLING PROPENSITY AND THE ADHESIVE PROPERTIES OF SICKLE RED BLOOD CELLS
por: N., CONRAN, et al.
Publicado: (2022)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

Association of mortality in the surgical ICU with plasma concentrations of plasminogen activator inhibitor-1 and soluble E-selectin
por: Yasuda, T, et al.
Publicado: (2008)

P-005: COMPARISON OF SICKLE SCAN AND HEMOTYPE SC AS POINT-OF-CARE NEWBORN SCREENING DIAGNOSTICS FOR SICKLE CELL DISEASE IN LUANDA, ANGOLA
por: B., SANTOS, et al.
Publicado: (2022)

5613480 REAL WORLD APPLICATIONS OF CLINICAL WHOLE BLOOD ADHESION (VCAM AND P-SELECTIN) BIOMARKERS IN A PEDIATRIC SCD POPULATION
por: Martin, O.Y., et al.
Publicado: (2023)

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: T., COATES, et al.
Publicado: (2022)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: S., VAN DER VEEN, et al.
Publicado: (2022)

P-089: EVALUATION OF SAFETY AND EFFICACY OF HBS-SAILIN®: A POTENT INGENIOUS ANTI-SICKLING AGENT THAT REDUCES PAIN AND IMPROVES THE QUALITY OF LIFE IN SICKLE CELL PATIENTS.
por: S., BHATT, et al.
Publicado: (2022)

Evaluation of sE-selectin and sPECAM-1 levels in patients diagnosed with food allergy
por: Graczyk, Malgorzata, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_grtg0ievq2tr3esf72o2b9pspe